Estimation of Human Absorbed Dose of ¹⁸⁸Re-Hynic-Bombesin Based on Biodistribution Data in Rats.

IF 1.5 4区医学 Q3 PHARMACOLOGY & PHARMACY Current radiopharmaceuticals Pub Date : 2023-01-01 DOI:10.2174/1874471015666220919124037

Sara Vosoughi, Nafise Salek, Hassan Yousefnia, Milad Delavari, Seyed Mahmoud Reza Aghamiri, Hassan Ranjbar

{"title":"Estimation of Human Absorbed Dose of 188Re-Hynic-Bombesin Based on Biodistribution Data in Rats.","authors":"Sara Vosoughi, Nafise Salek, Hassan Yousefnia, Milad Delavari, Seyed Mahmoud Reza Aghamiri, Hassan Ranjbar","doi":"10.2174/1874471015666220919124037","DOIUrl":null,"url":null,"abstract":"Background: HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The 188Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.Objective: The aim of this study was to estimate the absorbed dose due to 188Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.Methods: In this research, using bio-distribution data of 188Re-HYNIC-BBN in rats, its radiation absorbed dose of the adult human was calculated for different organs based on the MIRD dose calculation method.Results: A considerable equivalent dose amount of 188Re-Hynic-BBN (0.093 mGy/MBq) was accumulated in the prostate. Moreover, all other tissues except for the kidneys and pancreas approximately received insignificant absorbed doses.Conclusion: Since the acceptable absorbed dose for the complex was observed in the prostate, 188Re-Hynic-Bombesin can be regarded as a new potential agent for prostate cancer therapy.","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 1","pages":"64-70"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1874471015666220919124037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: HYNIC-Bombesin (BBN) is a potential peptide for targeted radionuclide therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies. The ¹⁸⁸Re-HYNICBBN is a promising radiopharmaceutical for use in prostate cancer therapy.

Objective: The aim of this study was to estimate the absorbed dose due to ¹⁸⁸Re-HYNIC-BBN radio-complex in human organs based on bio-distribution data of rats.

Methods: In this research, using bio-distribution data of ¹⁸⁸Re-HYNIC-BBN in rats, its radiation absorbed dose of the adult human was calculated for different organs based on the MIRD dose calculation method.

Results: A considerable equivalent dose amount of ¹⁸⁸Re-Hynic-BBN (0.093 mGy/MBq) was accumulated in the prostate. Moreover, all other tissues except for the kidneys and pancreas approximately received insignificant absorbed doses.

Conclusion: Since the acceptable absorbed dose for the complex was observed in the prostate, ¹⁸⁸Re-Hynic-Bombesin can be regarded as a new potential agent for prostate cancer therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于大鼠生物分布数据的188re - hynici - bombesin人体吸收剂量估算。

背景:hyic - bombesin (BBN)是一种潜在的靶向放射性核素治疗胃泌素释放肽受体(GRPr)阳性恶性肿瘤的肽。188Re-HYNICBBN是一种很有前途的用于前列腺癌治疗的放射性药物。目的:根据大鼠生物分布数据，估计188Re-HYNIC-BBN放射复合物在人体器官中的吸收剂量。方法:本研究利用188Re-HYNIC-BBN在大鼠体内的生物分布数据，基于MIRD剂量计算方法，计算其在成人不同器官的辐射吸收剂量。结果:188Re-Hynic-BBN在前列腺内积累了相当大的当量剂量(0.093 mGy/MBq)。此外，除肾脏和胰腺外，所有其他组织的吸收剂量几乎微不足道。结论:188re - hynici - bombesin在前列腺中有可接受的吸收剂量，可作为治疗前列腺癌的一种新的潜在药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current radiopharmaceuticals PHARMACOLOGY & PHARMACY-

CiteScore

3.20

自引率

4.30%

发文量